OS Therapies Files Q1 2024 10-Q Report

TL;DR

**OS Therapies Q1 2024 10-Q filed. Check financials.**

AI Summary

OS Therapies Inc. filed its quarterly report on Form 10-Q for the period ending March 31, 2024. The company, incorporated in Delaware with its principal executive offices in Rockville, Maryland, operates in the pharmaceutical preparations sector. The filing details its financial performance and operational status for the first quarter of 2024.

Why It Matters

This filing provides investors and stakeholders with an update on OS Therapies' financial health and operational progress during the first quarter of 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, OS Therapies likely faces inherent risks related to drug development, regulatory approvals, and market competition, which are typical for the sector.

Key Numbers

• 20850 — ZIP Code (Principal executive offices)
• 410-297-7793 — Phone Number (Registrant's telephone number)

Key Players & Entities

• OS Therapies Inc. (company) — Registrant
• March 31, 2024 (date) — Quarterly period end date
• Delaware (jurisdiction) — State of incorporation
• Rockville, Maryland (location) — Principal executive offices
• 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
• 333-271034 (commission_file_number) — SEC file number

FAQ

Filing Documents

• ea0206418-10q_osthera.htm (10-Q) — 638KB
• ea020641801ex31-1_osthera.htm (EX-31.1) — 7KB
• ea020641801ex31-2_osthera.htm (EX-31.2) — 7KB
• ea020641801ex32_osthera.htm (EX-32) — 6KB
• 0001213900-24-045141.txt ( ) — 4075KB
• osti-20240331.xsd (EX-101.SCH) — 52KB
• osti-20240331_cal.xml (EX-101.CAL) — 20KB
• osti-20240331_def.xml (EX-101.DEF) — 205KB
• osti-20240331_lab.xml (EX-101.LAB) — 385KB
• osti-20240331_pre.xml (EX-101.PRE) — 214KB
• ea0206418-10q_osthera_htm.xml (XML) — 465KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. 1 Balance Sheets as of March 31, 2024 and December 31, 2023 (unaudited) 1 2 3 4 Notes to the Financial Statements (unaudited) 5

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations. 22

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk. 33

Controls and Procedures

Item 4. Controls and Procedures. 33

OTHER INFORMATION

PART II. OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings. 34

Risk Factors

Item 1A. Risk Factors. 34

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 34

Exhibits

Item 6. Exhibits. 35 i PART I. FINANCIAL INFORMATION Item 1. Financial Statements OS Therapies Incorporated Balance Sheets (unaudited) March 31, 2024 December 31, 2023 ASSETS Current Assets Cash $ 100,231 $ 38,982 Deferred Offering Costs 941,338 751,050 Total Current Assets 1,041,569 790,032 Long Term Assets Fixed Assets (Net) 7,355 8,050 TOTAL ASSETS $ 1,048,924 $ 798,082 LIABILITIES AND STOCKHOLDERS' Deficit Current Liabilities Accounts Payable $ 2,799,120 $ 2,715,399 Accrued Interest on Convertible Notes 2,276,347 2,026,323 Accrued Expenses 162,500 162,500 Accrued Payroll and Payroll Taxes – Related Party 42,676 112,137 Accrued Payroll and Payroll Taxes 49,357 33,543 Redemption Premium 5,055,804 4,580,304 Short-Term Loan 100,000 — Preferred Dividends Payable 375,000 343,750 Convertible Notes – A (Net Debt Discount) 1,053,383 1,051,032 Convertible Notes – A (Related Party Net Debt Discount) 100,000 100,000 Convertible Notes – B (Net Debt Discount) 5,154,000 5,154,000 Convertible Notes – C (Net Debt Discount) 3,945,020 3,873,417 Convertible Notes – D (Net Debt Discount) 2,000,000 1,950,160 Convertible Notes – E (Net Debt Discount) 1,100,000 1,100,000 Convertible Notes – F (Net Debt Discount) 2,112,174 1,381,732 Make-whole Stock Liability 130,000 130,000 Total Current Liabilities 26,455,381 24,714,297 Long-Term Liabilities TEDCO Grant 100,000 100,000 Total Long-Term Liabilities 100,000 100,000 Total Liabilities 26,555,381 24,814,297 STOCKHOLDERS' DEFICIT Common Stock, par value $ 0.001 , 50,000,000 shares authorized, 11,982,082 and 10,680,000 issued and outstanding, respectively 11,982 10,680 Preferred Stock, par value $ 0.001 , 5,000,000 shares authorized, 0 and 1,302,082 shares Preferred Stock A issued and outstanding, respectively — 1,302 Additional paid-in capital 5,489,990 5,489,990 Accumulated deficit ( 31,008,429 ) ( 2

View Full Filing

View this 10-Q filing on SEC EDGAR